Is ENTX or TKNO more profitable?

Entera Bio has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Alpha Teknova -41.07% -24.32% -16.34%

Is ENTX or FBRX more profitable?

Entera Bio's return on equity of -83.31% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Forte Biosciences N/A -106.17% -85.50%

Does the media prefer ENTX or FBRX?

In the previous week, Forte Biosciences had 2 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for Forte Biosciences and 2 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Forte Biosciences' score of 0.47 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Forte Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVXL or ENTX more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% Entera Bio N/A -83.31% -70.83%

Is ENTX or FULC more profitable?

Fulcrum Therapeutics' return on equity of -27.80% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Fulcrum Therapeutics N/A -27.80% -26.32%

Does the media refer more to ENTX or FULC?

In the previous week, Entera Bio and Entera Bio both had 2 articles in the media. Entera Bio's average media sentiment score of 1.87 beat Fulcrum Therapeutics' score of 0.19 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fulcrum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ENTX or INDP?

Entera Bio presently has a consensus target price of $9.00, suggesting a potential upside of 631.71%. Given Entera Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Entera Bio is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ENTX or INDP more profitable?

Entera Bio's return on equity of -83.31% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Indaptus Therapeutics N/A -1,030.07% -299.69%

Entera Bio (ENTX) Competitors

$1.23 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.23 0.00 (-0.41%)

As of 06/12/2026 07:49 PM Eastern

Compare

ENTX vs. TKNO, FBRX, AVXL, FULC, and INDP

Should you buy Entera Bio stock or one of its competitors? MarketBeat compares Entera Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entera Bio include Alpha Teknova (TKNO), Forte Biosciences (FBRX), Anavex Life Sciences (AVXL), Fulcrum Therapeutics (FULC), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry.

How does Entera Bio compare to Alpha Teknova?

Entera Bio (NASDAQ:ENTX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 12.5% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Entera Bio had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for Entera Bio and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Entera Bio's score of 1.87 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Overall Sentiment
Entera Bio	Very Positive
Alpha Teknova	Very Positive

Entera Bio has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Entera Bio currently has a consensus target price of $9.00, indicating a potential upside of 631.71%. Alpha Teknova has a consensus target price of $8.00, indicating a potential upside of 90.48%. Given Entera Bio's higher probable upside, equities research analysts plainly believe Entera Bio is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Entera Bio has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Alpha Teknova	-41.07%	-24.32%	-16.34%

Entera Bio has higher earnings, but lower revenue than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	1,515.67	-$11.44M	-$0.27	N/A
Alpha Teknova	$40.52M	5.56	-$17.26M	-$0.32	N/A

Summary

Entera Bio beats Alpha Teknova on 10 of the 17 factors compared between the two stocks.

How does Entera Bio compare to Forte Biosciences?

Entera Bio (NASDAQ:ENTX) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Entera Bio has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, meaning that its share price is 187% more volatile than the broader market.

In the previous week, Forte Biosciences had 2 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for Forte Biosciences and 2 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Forte Biosciences' score of 0.47 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Forte Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio has higher revenue and earnings than Forte Biosciences. Entera Bio is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	1,515.67	-$11.44M	-$0.27	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Entera Bio's return on equity of -83.31% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Forte Biosciences	N/A	-106.17%	-85.50%

Entera Bio currently has a consensus target price of $9.00, suggesting a potential upside of 631.71%. Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 281.55%. Given Entera Bio's higher probable upside, analysts clearly believe Entera Bio is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Entera Bio beats Forte Biosciences on 8 of the 14 factors compared between the two stocks.

How does Entera Bio compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anavex Life Sciences' return on equity of -38.76% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Entera Bio	N/A	-83.31%	-70.83%

Entera Bio has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Entera Bio	$40K	1,515.67	-$11.44M	-$0.27	N/A

Anavex Life Sciences has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

In the previous week, Entera Bio had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for Entera Bio and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 equaled Entera Bio'saverage media sentiment score.

Company	Overall Sentiment
Anavex Life Sciences	Very Positive
Entera Bio	Very Positive

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 753.33%. Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 631.71%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Anavex Life Sciences is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Anavex Life Sciences beats Entera Bio on 7 of the 13 factors compared between the two stocks.

How does Entera Bio compare to Fulcrum Therapeutics?

Entera Bio (NASDAQ:ENTX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Entera Bio has higher earnings, but lower revenue than Fulcrum Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	1,515.67	-$11.44M	-$0.27	N/A
Fulcrum Therapeutics	$80M	2.87	-$74.88M	-$1.15	N/A

Entera Bio currently has a consensus target price of $9.00, suggesting a potential upside of 631.71%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 137.68%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts plainly believe Entera Bio is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Entera Bio and Entera Bio both had 2 articles in the media. Entera Bio's average media sentiment score of 1.87 beat Fulcrum Therapeutics' score of 0.19 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Fulcrum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics' return on equity of -27.80% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Entera Bio has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the broader market.

Summary

Entera Bio beats Fulcrum Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Entera Bio compare to Indaptus Therapeutics?

Entera Bio (NASDAQ:ENTX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Entera Bio and Entera Bio both had 2 articles in the media. Entera Bio's average media sentiment score of 1.87 beat Indaptus Therapeutics' score of 1.44 indicating that Entera Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Entera Bio	Very Positive
Indaptus Therapeutics	Positive

Entera Bio presently has a consensus target price of $9.00, suggesting a potential upside of 631.71%. Given Entera Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Entera Bio is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Entera Bio's return on equity of -83.31% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Entera Bio has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Entera Bio has higher revenue and earnings than Indaptus Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	1,515.67	-$11.44M	-$0.27	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Summary

Entera Bio beats Indaptus Therapeutics on 11 of the 13 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTX vs. The Competition

Export

Metric	Entera Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$60.63M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-4.56	20.00	24.00	24.42
Price / Sales	1,515.67	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	4.24	8.32	10.60	6.82
Net Income	-$11.44M	$23.94M	$3.57B	$337.56M
7 Day Performance	2.50%	1.84%	0.59%	1.16%
1 Month Performance	-2.38%	-0.04%	1.54%	3.16%
1 Year Performance	-33.87%	44.82%	25.41%	30.60%

Entera Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTX Entera Bio	2.5883 of 5 stars	$1.23 flat	$9.00 +631.7%	-33.9%	$60.63M	$40K	N/A	20	Positive News Gap Down
TKNO Alpha Teknova	2.5809 of 5 stars	$4.45 -4.4%	$8.00 +80.0%	-23.4%	$238.30M	$40.52M	N/A	240	Positive News Gap Down
FBRX Forte Biosciences	1.8521 of 5 stars	$17.02 +8.6%	$67.00 +293.7%	+45.2%	$236.39M	N/A	N/A	5
AVXL Anavex Life Sciences	2.1258 of 5 stars	$2.54 -3.2%	$21.33 +741.6%	-68.9%	$234.92M	N/A	N/A	40
FULC Fulcrum Therapeutics	2.5508 of 5 stars	$3.51 +1.9%	$8.20 +134.0%	-49.6%	$233.54M	$80M	N/A	100	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entera Bio (ENTX) Competitors

ENTX vs. TKNO, FBRX, AVXL, FULC, and INDP

How does Entera Bio compare to Alpha Teknova?

Summary

How does Entera Bio compare to Forte Biosciences?

Summary

How does Entera Bio compare to Anavex Life Sciences?

Summary

How does Entera Bio compare to Fulcrum Therapeutics?

Summary

How does Entera Bio compare to Indaptus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entera Bio (ENTX) Competitors

ENTX vs. TKNO, FBRX, AVXL, FULC, and INDP

How does Entera Bio compare to Alpha Teknova?

Do insiders and institutionals have more ownership in ENTX or TKNO?

Does the media prefer ENTX or TKNO?

Which has more risk and volatility, ENTX or TKNO?

Do analysts rate ENTX or TKNO?

Is ENTX or TKNO more profitable?

Which has stronger earnings and valuation, ENTX or TKNO?

Summary

How does Entera Bio compare to Forte Biosciences?

Which has more volatility & risk, ENTX or FBRX?

Does the media prefer ENTX or FBRX?

Which has stronger earnings and valuation, ENTX or FBRX?

Is ENTX or FBRX more profitable?

Do analysts prefer ENTX or FBRX?

Do insiders & institutionals hold more shares of ENTX or FBRX?

Summary

How does Entera Bio compare to Anavex Life Sciences?

Do insiders and institutionals have more ownership in AVXL or ENTX?

Is AVXL or ENTX more profitable?

Which has preferable earnings and valuation, AVXL or ENTX?

Which has more volatility and risk, AVXL or ENTX?

Does the media favor AVXL or ENTX?

Do analysts prefer AVXL or ENTX?

Summary

How does Entera Bio compare to Fulcrum Therapeutics?

Which has better earnings and valuation, ENTX or FULC?

Do analysts recommend ENTX or FULC?

Does the media refer more to ENTX or FULC?

Is ENTX or FULC more profitable?

Do institutionals & insiders hold more shares of ENTX or FULC?

Which has more risk and volatility, ENTX or FULC?

Summary

How does Entera Bio compare to Indaptus Therapeutics?

Do institutionals and insiders hold more shares of ENTX or INDP?

Does the media prefer ENTX or INDP?

Do analysts recommend ENTX or INDP?

Is ENTX or INDP more profitable?

Which has more volatility and risk, ENTX or INDP?

Which has higher valuation and earnings, ENTX or INDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools